HLA class I, KIR polymorphisms and KIR-HLA interactions in epithelial ovarian cancer: associations with susceptibility, platinum resistance and survival
Background Natural killer (NK) cell activity is regulated by killer-cell immunoglobulin-like receptors (KIR) and their HLA class I ligands. Whether specific KIR/HLA genotypes influence susceptibility to, or prognosis of, epithelial ovarian cancer (EOC) remains poorly defined. Methods We genotyped 16 KIR genes and HLA-A, -B and -C alleles in 64 women with EOC and 54 age-comparable cancer-free controls. Within the EOC cohort, we compared KIR/HLA distribution between platinum-sensitive (n=53) and platinum-resistant (n=11) patients, and evaluated progression-free survival (PFS) and overall survival (OS) by Kaplan-Meier and multivariable Cox regression adjusted for BRCA1/2 status, homologous recombination deficiency (HRD), FIGO stage and ECOG status. Given the number of comparisons performed, findings are reported as exploratory and hypothesis-generating. Results HLA-A*11:01 was overrepresented in cases (28.1% vs 11.1%; OR = 3.13), while HLA-B*38:01 was underrepresented (3.1% vs 14.8%; OR = 0.19). No individual KIR gene or canonical KIR-HLA pair differed between cases and controls. Within the EOC cohort, HLA-A*29:02 and HLA-B*37:01 were more frequent among platinum-resistant patients; in a backward-elimination multivariable Cox analysis, only HLA-B*37:01 and ECOG ≥2 remained independent predictors of shorter PFS and OS, with BRCA1/2 mutation additionally significant for PFS. Co-presence of the receptor KIR2DS1 with HLA-C2 was associated with a higher crude relapse rate (90.0% vs 61.4%; p=0.022), not confirmed by a time-to-event analysis (p=0.52). Conclusion HLA-A*11:01 and HLA-B*38:01 were associated with EOC susceptibility, and HLA-A*29:02 and HLA-B*37:01 were associated with platinum resistance, but only the rare HLA-B*37:01 remained an independent predictor of survival after adjustment; these exploratory findings warrant validation in larger, independent cohorts.
Authors
- Luis Perez-Bartivas
- Rafael González Fernández (ORCID: https://orcid.org/0000-0001-5157-6606)
- Bárbara Manzanares Martin
- Maria Jesus Rubio Pérez
- Beatriz Teso Martín
- Enrique Aranda Aguilar
- Icíar De La Fuente DomÃnguez (ORCID: https://orcid.org/0000-0003-2573-8039)
- Juan de la Haba Rodríguez
- David Ponferrada Álvarez
- Javier Caballero Villarraso
Institutions
- Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
- Hospital Universitario Reina Sofía (ES)
- University of Córdoba (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3389/fimmu.2026.1971500
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.00